Brazil

Biomm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BRAZIL Brazil

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil

Lead Product(s): Leronlimab

Therapeutic Area: Infections and Infectious Diseases Product Name: Vyrologix

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2021

Details:

Marketed as Vyrologix, leronlimab is an investigational humanised immunoglobulin G4 monoclonal antibody that hinders C-C chemokine receptor type 5 (CCR5).

Uniao Quimica Farmaceutica Nacional

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BRAZIL Brazil

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Brazilian Approval of Sputnik V Vaccine Delayed by Missing Data

Lead Product(s): Gam-COVID-Vac

Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 17, 2021

Details:

Documents supporting drugmaker Uniao Quimica’s application for emergency use of Sputnik V have been returned to the company because they did not meet its minimum criteria.